Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N E Kay

Showing results (111-120 of 149) with videos related to

Pageof 15
Sort By:
Clinical and Diagnostic Laboratory Immunology|July 1, 1994
Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies?K Kuus-Reichel, L S Grauer, L M Karavodin, et al.
Clinical Immunology and Immunopathology|July 1, 1975
Hemolytic anemia with serum and erythrocyte-bound low-molecular-weight IgMN E Kay, S D Douglas, J J Mond, et al.
Leukemia & Lymphoma|January 1, 1995
Sequential phenotyping of myeloma patients on chemotherapy: persistence of activated T-cells and natural killer cellsN E Kay, M M Oken, R Kyle, et al.
Blood|August 1, 1982
Fibronectin enhances in vitro monocyte-macrophage-mediated tumoricidal activityR T Perri, N E Kay, J McCarthy, et al.
Leukemia|November 25, 2015
Axl activates fibroblast growth factor receptor pathway to potentiate survival signals in B-cell chronic lymphocytic leukemia cellsS Sinha, J Boysen, M Nelson, et al.
The New England Journal of Medicine|April 9, 1992
Hypoglycemia due to a monoclonal insulin-binding antibody in multiple myelomaB Redmon, K L Pyzdrowski, M K Elson, et al.
The Journal of Clinical Investigation|July 1, 1979
Modulation of neutrophil function by lysozyme. Potential negative feedback system of inflammationL I Gordon, S D Douglas, N E Kay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1986
Clinical trial of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin's lymphomas and chronic lymphocytic leukemia. An Eastern Cooperative Oncology Group pilot studyM J O'Connell, J P Colgan, M M Oken, et al.
Leukemia|April 1, 2005
ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotypeJ C Nolz, R C Tschumper, B T Pittner, et al.
Blood|November 15, 1995
Circulating CD19+ blood cell levels in myeloma. ECOG Myeloma Clinical Trials Laboratory Study GroupN E Kay, M M Oken, N Bone, et al.
Pageof 15

Showing results (111-120 of 149) with videos related to

Sort By:
Pageof 15
Clinical and Diagnostic Laboratory Immunology|July 1, 1994
Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies?K Kuus-Reichel, L S Grauer, L M Karavodin, et al.
Clinical Immunology and Immunopathology|July 1, 1975
Hemolytic anemia with serum and erythrocyte-bound low-molecular-weight IgMN E Kay, S D Douglas, J J Mond, et al.
Leukemia & Lymphoma|January 1, 1995
Sequential phenotyping of myeloma patients on chemotherapy: persistence of activated T-cells and natural killer cellsN E Kay, M M Oken, R Kyle, et al.
Blood|August 1, 1982
Fibronectin enhances in vitro monocyte-macrophage-mediated tumoricidal activityR T Perri, N E Kay, J McCarthy, et al.
Leukemia|November 25, 2015
Axl activates fibroblast growth factor receptor pathway to potentiate survival signals in B-cell chronic lymphocytic leukemia cellsS Sinha, J Boysen, M Nelson, et al.
The New England Journal of Medicine|April 9, 1992
Hypoglycemia due to a monoclonal insulin-binding antibody in multiple myelomaB Redmon, K L Pyzdrowski, M K Elson, et al.
The Journal of Clinical Investigation|July 1, 1979
Modulation of neutrophil function by lysozyme. Potential negative feedback system of inflammationL I Gordon, S D Douglas, N E Kay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1986
Clinical trial of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin's lymphomas and chronic lymphocytic leukemia. An Eastern Cooperative Oncology Group pilot studyM J O'Connell, J P Colgan, M M Oken, et al.
Leukemia|April 1, 2005
ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotypeJ C Nolz, R C Tschumper, B T Pittner, et al.
Blood|November 15, 1995
Circulating CD19+ blood cell levels in myeloma. ECOG Myeloma Clinical Trials Laboratory Study GroupN E Kay, M M Oken, N Bone, et al.
Pageof 15